India Drug Regulator Increases Semaglutide Inspections
Topics
Developing
- 862d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 862d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 862d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 862d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
“patent protection ended in India for semi-glutide. the active ingredient in B. rolling out generic versions of somaglotide, cutting treatment costs by up to 70% in some cases.”
“At least half a dozen Indian drug makers have launched generic semi-glutide products. From online platforms to neighbourhood pharmacies, GLP-1 medicines are becoming widely available and far more affordable”
“At least half a dozen Indian drug makers have launched generic semi-glutide products. From online platforms to neighbourhood pharmacies, GLP-1 medicines are becoming widely available and far more affordable that has prompted India's drug regulator to step up inspections to prevent unauthorised sale.”
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade